AzTrials
AzTrials

AsthmaPhase 2NCT01501942

Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma

A Phase 2 study testing AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide and Buffered Saline in people with Asthma, run by AIM Therapeutics Inc. at 2 sites in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a Phase II, double-blind, placebo-controlled, cross-over trial to evaluate the efficacy of AIM-102 for the treatment of allergen-induced asthma. Individuals with stable, mild to moderate allergic asthma by American Thoracic Society (ATS) criteria (1), with a history of episodic wheeze and shortness of breath… Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Asthma
What is being tested?
AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide and Buffered Saline
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
11 participants
Where
2 sitesCanada
Study dates
Feb 2012to Mar 2013
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • The following inclusion must be met for study entry (Part 1 - Screening):
  • Males and females between ≥ 18 and ≤ 65 years of age.
  • Able and willing to provide written informed consent to participate in the study, in accordance with ICH GCP requirements.
  • Non or ex-smoker, defined by an ex-smoker is defined as someone who completely stopped smoking for at least 12 months before Visit 1 of this study.
  • Able to adhere to study procedures.
  • In good general health without clinically significant medical history (see also Exclusion criteria below).
Show all 21Show fewer
  • Physical examination and laboratory results within the normal ranges, if not within the ranges, they must be without clinically significance within 28 days prior to dosing.
  • Available for follow-up for the duration of the study (i.e. up to 10 weeks, including the Screening and Treatment Phases).
  • Mild to moderate, stable, allergic asthma by the ATS criteria (1)
  • History of episodic wheeze and shortness of breath; FEV1 at baseline at least 70% of the predicted value
  • Males agree to practice adequate contraception throughout the duration of the study and up to one month after drug administration.
  • FEMALE-SPECIFIC INCLUSION CRITERIA:
  • All females must have a negative serum pregnancy test at Screening Days -5 to -1 (Visit 5) and a negative urine pregnancy test at Day 1 of each Treatment Phase prior to dosing (Visits 6 and 11).
  • A female patient must meet one of the following criteria:
  • No reproductive potential, defined as: menopausal for at least two years or surgically sterile for at least six months (i.e. has undergone hysterectomy, bilateral oophorectomy or tubal ligation) OR
  • Participant agrees to be heterosexually inactive from Screening Visit 1 until one month post final dose OR
  • Participant agrees to consistently practice adequate contraception from Screening Visit 1 until one month post final dose by one of the following methods, two methods must be used if hormonal contraception is used: Contraceptive pills (stable dose for at least 2 months prior to dosing on Day 1 (Visit 6) or patch, Norplant or Provera; intrauterine device (IUD), condom with spermicide or diaphragm (cervical cap) with spermicide.
  • In addition the inclusion criteria above, the following inclusion criteria must be met for entry into the Dosing Phase (Part 2):
  • Positive methacholine challenge (PC20 ≤ 16 mg/ml)
  • Positive skin-prick test to common aeroallergens (including cat, dust mite, grass, pollen)
  • Positive allergen-induced early and late airway bronchoconstriction

Who cannot join

  • A patient will be excluded if one or more of the following conditions apply.
  • FEMALE ONLY EXCLUSIONS:
  • Females who are pregnant or are lactating
  • Females of childbearing potential who refuse to use an acceptable contraceptive regimen throughout the entire duration of the study (from the Screening visit until study completion) and for one month post dosing
  • RELEVANT MEDICAL HISTORY:
  • Use of any nicotine containing products within 12 months prior to Screening or a smoking history > 10 pack years
Show all 38Show fewer
  • A worsening of asthma or a respiratory tract infection within 6 weeks preceding study entry
  • Clinically significant and relevant abnormal findings in the clinical history, physical examination, ECG, or laboratory tests during Screening that would interfere with the objectives of the study or that would in the Investigator's opinion preclude safe completion of the study. Abnormal clinical history and/or findings could include:
  • Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
  • Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
  • Presence of out-of-range cardiac interval (PR < 110 msec, PR > 200 msec, QRS < 60 msec, QRS > 110 msec and QTc > 440 msec) on the screening ECG or other clinically significant ECG abnormalities
  • Autoimmune disease or immunodeficiency
  • History of clinically significant hypotensive episodes or symptoms of fainting, dizziness, or lightheadedness
  • Abnormal chest X-ray either at or within 1 year of Screening
  • Current acute or chronic illness (including infection) or recent recovery from acute illness which could, in the opinion of the Investigator, alter immune cell function (e.g., flu, cold or other respiratory infection, etc.)
  • Presence of a transplanted tissue or organ
  • Any evidence of malignancy [active and/or treated] within the previous five years or malignancy that is likely to recur during the period of the study
  • History of diabetes mellitus (Type I or II)
  • Thyroid disease (including thyroidectomy), requiring medication within the past 12 months
  • Asthma that is unstable or required emergent/urgent care, hospitalization or intubation during the past two years or that requires the use of oral or intravenous corticosteroids
  • Bleeding disorders (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions)
  • Major surgical procedure or significant traumatic injury within 12 months prior to the study treatment administration, OR minor surgery within one month prior to the study treatment administration or anticipation of the need for any surgery during the course of the study
  • Any other significant concomitant illness or injury that would interfere with the patient's participation in the study
  • Any clinically significant illness in the previous 28 days before the first day of dosing in either of the Treatment Phases of this study
  • Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and St John's Wort), in the previous 30 days before Day 1 of this study
  • History of drug abuse including marijuana, PCP, cocaine, crack, LSD or other identified street drugs
  • Positive results to HIV, HbsAg or anti-HCV tests at Screening
  • Lung disease other than mild to moderate allergic asthma
  • Concomitant disease or condition which could interfere with the conduct of the study, or for which the treatment might interfere with the conduct of the study, or which would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this study, including, but not limited to, cancer, alcoholism, drug dependency or abuse, or psychiatric disease
  • Recent (less than 1 year) history of alcohol dependency
  • Any other medical, social, or geographical factor, which would make it unlikely that the patient will comply with study procedures (e.g. history of non-compliance)
  • PROHIBITED MEDICATION USE
  • Systemic immunosuppressive or cytotoxic drug therapy (systemic corticosteroids, cyclophosphamide, methotrexate, cyclosporine, azathioprine, etc.) taken within two months prior to the study treatment administration. Corticosteroid nasal spray (e.g. for allergic rhinitis) or inhaled corticosteroid must have a 30 day washout prior to randomization (Visit 6)
  • Significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
  • Use of any investigational therapy or participation in another clinical study within 30 days prior to the study drug administration
  • Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within 48 hr of dosing or aspirin within seven days of dosing and any time during the Treatment Phases
  • Have chronic use of any other medication for treatment of allergic lung disease other than short-acting ß2-agonists or ipratropium bromide
  • Use of caffeine-containing products or medications for 12 hr or alcohol or over the counter drugs including cold and allergy medications for 48 hr or inhaled bronchodilators for 8 hr prior to methacholine and allergen challenges

Trial locations and contacts

2 sites in 1 country.

Canada2 sites

  • McMaster University

    Hamilton, Ontario, L8N 3Z5

  • Institut de cardiologie et de pneumologie de l'Hôpital Laval

    Laval, Quebec, G1V 4G5

Other trials in Canada

About this study

Official title: A Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma

This is a Phase II, double-blind, placebo-controlled, cross-over trial to evaluate the efficacy of AIM-102 for the treatment of allergen-induced asthma. Individuals with stable, mild to moderate allergic asthma by American Thoracic Society (ATS) criteria (1), with a history of episodic wheeze and shortness of breath, will be eligible for enrollment.

The patients will receive 4 consecutive days of dosing of AIM-102 or placebo (inactive product) with an allergen challenge on day 3 of dosing to see how the patient's lung function is changed by using AIM-102 or placebo.

Read the detailed description

This is a Phase II, double-blind, placebo-controlled, cross-over trial to evaluate the efficacy of AIM-102 for the treatment of allergen-induced asthma. Individuals with stable, mild to moderate allergic asthma by American Thoracic Society (ATS) criteria (1), with a history of episodic wheeze and shortness of breath, will be eligible for enrollment.

The study is divided into 2 parts.

Part 1: Screening

Patients who meet all entry criteria will be screened with a history, physical examination, spirometry, and routine laboratory tests. If they continue to meet entry criteria, their atopic status will be documented by skin testing against common airborne allergens (including cat, dust mite, grass, pollen). Twenty-four (24) hr later, an allergen challenge will be performed to confirm the presence of an Early Asthmatic Response (EAR) and Late Asthmatic Response (LAR). Methacholine PC20 and sputum differentials will be performed before and after allergen challenges. Only patients with a documented early and late asthmatic response to inhaled incremental allergen challenge will be eligible for entry into Part 2 of the study.

Part 2: Dosing and Follow-up

Patients will be assigned to receive drug and placebo in a random order, with at least a two week washout between treatment periods. Spirometry, vital signs, and asthma symptomatology, methacholine challenge, sputum differentials will be evaluated before the first dose and again 24 hr before allergen challenge. Allergen challenge will be performed in the morning of Day 3 of dosing, post-dose, with spirometry measured until seven hr post-challenge. Sputum will also be induced at seven hr following the allergen challenge. Methacholine challenge and sputum induction will be performed 24 hr after allergen challenges. Any adverse events (AEs) and asthma symptoms will be evaluated at each clinic visit. A physical examination, vital signs, ECG, spirometry and laboratory tests will be repeated at the termination visit.

Conditions
Asthma
Being tested
AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide, Buffered Saline
Keywords
Asthma, Allergen induced asthma, ATS Criteria (1)
Medical subject headings
Asthma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptideDrug

    AIM-102 is supplied as an oral solution. Dose is 15 mg of AIM-102 per kg of patient weight measured on Treatment Day 1 of each treatment phase The study drug will be administered for 4 consecutive days with at least a 2 week wash-out period prior to crossing over to the alternative treatment for 4 days.

  • Buffered SalineDrug

    The matching placebo is an oral solution of phosphate buffered saline

Study groups in NCT01501942
Study groupRoleWhat they receive
ActiveExperimentalThe active drug product is an oral solution of AIM-102 in phosphate buffered saline at a concentration of 35.0 mg/ml.
Receives: Drug: AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide
Inactive productPlacebo comparatorThe matching placebo is an oral solution of phosphate buffered saline
Receives: Drug: Buffered Saline

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline of the allergen-induced late asthmatic response (LAR) between AIM-102 and placebo.

    Spirometry and the presence and severity of asthma symptoms will be assessed immediately before and immediately after each dose. Baseline and allergen-induced methacholine PC20, allergen-induced bronchoconstriction and allergen-induced airway inflammation will be assessed.

    AUC and maximum decrease in FEV1 for the late response will be compared between treatments using a one-way analysis of variance for the effects of treatment.

    Measured: Pre dose(s) and post dose(s) and 7 and 24 hours post allergen challenge

Secondary outcomes (5)

  1. Early Asthmatic Response

    Spirometry \& the presence and severity of asthma symptoms will be assessed immediately before and immediately after each dose. Baseline and allergen-induced methacholine PC20, allergen-induced bronchoconstriction and allergen-induced airway inflammation will be assessed.

    Allergen-induced increase in airway responsiveness is assessed by measuring the log methacholine PC20 difference from 24 hours before to 24 hours after allergen challenge.

    Measured: Pre-dose(s) and post-dose(s) and 3 hours after allergen challenge

  2. • Comparison of the allergen-induced changes in sputum eosinophils at 7 hr and 24 hr post allergen, between the AIM-102 and placebo

    Allergen-induced sputum eosinophils will be compared between treatments using a two-way analysis of variance for the effects of treatment and time.

    Measured: Pre-dose and post-dose(s) and 7 and 24 hours post allergen challenge

  3. Comparison of allergen-induced inflammatory mediators at 7 hr and 24 hr post allergen, between AIM-102 and placebo.

    The allergen-induced airway inflammatory cells will be compared between treatments using a two-way analysis of variance.

    Measured: Pre-dose and post-dose(s) and 7 and 24 hours post allergen challenge

  4. Comparison of the allergen-induced airway hyperresponsiveness at 24 hours (hr) post allergen, between AIM-102 and placebo

    The allergen-induced airway hyperresponsiveness will be compared between treatments using a one-way analysis of variance for the effects of treatment.

    Measured: Pre-dose and 24 hours post allergen challenge

  5. To determine the pharmacokinetic (PK) profile of AIM-102 in normal healthy mild to moderate asthmatic patients upon repeat dosing of AIM-102

    Drug plasma concentration data will be analyzed using a non-compartmental approach to obtain the following PK parameters:

    • peak plasma concentration
    • time to peak plasma concentration
    • elimination rate constant
    • terminal or elimination half-life
    • area under the concentration time curve from time 0 to last quantifiable concentration
    • area under the concentration time curve from time 0, extrapolated to infinity
    • oral clearance
    • oral volume of distribution

    Measured: Pre-dose for dosing Days 1, 2, 3, 4, & an optional Day 5, additional samples on Day 3 post-dose & allergen challenge,pre-dose, 1.5, 3, 4.5, 6, & 7.5 hr post-dose

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Dec 2011 (estimated)
  2. Study startFeb 2012
  3. Primary completionFeb 2013
  4. Study completionMar 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
11 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01501942
Sponsor's protocol ID
AIM102-201
Status last verified
Feb 2014
First submitted
26 Dec 2011
Last updated
14 Feb 2014
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide and Buffered Saline in people with Asthma, run by AIM Therapeutics Inc. at 2 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 21 inclusion and 38 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Feb 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline of the allergen-induced late asthmatic response (LAR) between AIM-102 and placebo. (time frame: Pre dose(s) and post dose(s) and 7 and 24 hours post allergen challenge). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01501942.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2014.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in